{"id":"W3087498123","doi":"10.1016/j.cllc.2020.09.007","title":"Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non–Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":13,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Guardant Health; Roche Diagnostics; Bristol-Myers Squibb Canada; Genentech; AstraZeneca; Fundación Agencia Aragonesa para la Investigación y el Desarrollo; C17 Children's Cancer and Blood Disorders; Astellas Pharma; University of Texas Southwestern Medical Center; Merck Sharp and Dohme; Takeda Pharmaceuticals U.S.A.; Simmons College; AbbVie; University of Arizona Cancer Center; Alexion Pharmaceuticals; PharmaMar; Novartis; Celgene; Boehringer Ingelheim; Ariad Pharmaceuticals; Roche; Merck; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; Sarah Cannon Research Institute","keywords":"Medicine; Paclitaxel; Hazard ratio; Internal medicine; Clinical endpoint; Lung cancer; Carboplatin; Interim analysis; Gastroenterology; Randomized controlled trial; Progression-free survival; Confidence interval; Oncology; Cancer; Surgery; Chemotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001207375,0.001489049,0.002038148,0.0003648877,0.0003618451,0.001027277,0.0008540575,0.001491977,0.003933864],"category_scores_gemma":[0.0006594635,0.0005104435,0.001316698,0.0004076522,0.001061416,0.0009036069,0.0003433159,0.003007826,0.0009739673],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009278582,"about_ca_system_score_gemma":0.001338194,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001141411,"about_ca_topic_score_gemma":0.002011978,"domain_scores_codex":[0.9996831,0.0001150254,0.00001400369,0.00007614839,0.00003389017,0.00007782926],"domain_scores_gemma":[0.9996252,0.00007726065,0.00007254949,0.00003604231,0.00003145363,0.0001573854],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8829405,0.03521323,0.000801906,0.0009072057,0.00093257,0.00007395544,0.0001132357,0.001291748,0.01675065,0.0003154535,0.002379772,0.05827976],"study_design_scores_gemma":[0.7197432,0.273223,0.001648957,0.00003778072,0.0003932909,0.00005976265,0.00003399103,0.0009450316,0.002311372,0.0001963908,0.001383692,0.00002354397],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9899003,0.003313482,0.0007851173,0.0005853925,0.0004165438,0.002545576,0.0004417761,0.0001383116,0.001873401],"genre_scores_gemma":[0.9861525,0.002757496,0.001706535,0.0009601142,0.0002819765,0.003084233,0.0008635216,0.00004218129,0.004151356],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003933864,"threshold_uncertainty_score":0.01316011,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04164487511171669,"score_gpt":0.3698253989518835,"score_spread":0.3281805238401668,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}